Management of Combined Pulmonary Fibrosis and Emphysema
Patients with CPFE should be managed with antifibrotic therapy (nintedanib or pirfenidone), smoking cessation, oxygen supplementation, and close monitoring for complications including pulmonary hypertension and lung cancer, following the same treatment paradigm as idiopathic pulmonary fibrosis while recognizing that FVC alone is unreliable for disease monitoring.
Initial Assessment and Risk Stratification
CPFE predominantly affects male smokers (>90% with >40 pack-year history) aged 65-70 years 1. At diagnosis, evaluate for:
- Baseline DLCO: This is the single most important prognostic marker—baseline DLCO independently predicts mortality (HR 0.934) 2 and should guide transplant referral decisions
- Pulmonary hypertension: Present in 47-90% of patients and significantly impacts survival 1, 3
- Lung cancer screening: Incidence ranges from 22-46%, predominantly squamous cell carcinoma 1
- Six-minute walk test with desaturation: Exercise-induced hypoxemia is nearly universal and correlates with mortality 2
Pharmacological Management
Antifibrotic Therapy
Initiate antifibrotic therapy (nintedanib or pirfenidone) at diagnosis, following the same approach as IPF 4. Despite recent concerns about potential increased mortality trends in retrospective data 5, the evidence shows:
- Antifibrotics produce comparable functional outcomes in CPFE versus IPF alone 6
- DLCO decline occurs in both groups but remains below futility thresholds 6
- The majority of CPFE patients remain undertreated (only 30-36% receive appropriate therapy) 2
Critical caveat: The suggestion of increased mortality with antifibrotics 5 likely represents "sicker patient" bias rather than true harm, as these patients had more severe disease at baseline.
Smoking Cessation
Mandatory intervention given that smoking is the primary modifiable risk factor 1, 7, 3.
Monitoring Strategy
Do not rely on FVC alone for disease monitoring in CPFE—this is a critical pitfall. The emphysema component masks restrictive changes, producing falsely preserved lung volumes 2.
Instead, monitor every 3-6 months with 4, 2:
- DLCO (corrected for hemoglobin): Absolute decline >10% within 1 year indicates progression
- Six-minute walk test: Assess desaturation and distance
- Symptom assessment: Worsening dyspnea or cough
- Annual HRCT: Essential for detecting radiological progression (increased traction bronchiectasis, new reticulation, increased honeycombing) 4
DLCO decline at year 1 significantly predicts radiological progression (p=0.039) 2, making it more reliable than FVC in this population.
Complication Management
Pulmonary Hypertension
Screen with echocardiography at baseline and when clinically indicated. Higher pulmonary artery pressures independently predict mortality 2.
Lung Cancer Surveillance
Maintain heightened vigilance with annual HRCT given the 22-46% incidence 1. Lung cancer is an independent prognostic factor that alters outcomes 7.
Acute Exacerbations
Occur in 20-28% of patients 1. Treat with corticosteroids per IPF guidelines 4, though mechanical ventilation is not recommended for most patients with respiratory failure.
Supportive Care
- Oxygen therapy: Required in >70% of patients long-term 1. Device use (LTOT/NIMV) independently predicts mortality (HR 2.48) 6
- Pulmonary rehabilitation: Recommended as nonpharmacological therapy 4
- Palliative care: Integrate early for symptom management (dyspnea, cough, anxiety) 4
Transplant Evaluation
Refer for lung transplantation evaluation at diagnosis if increased mortality risk, specifically:
Mean survival is 5.08-5.68 years with 5-year survival of 35-67.8% 2, 1—comparable to or worse than IPF alone, justifying early transplant consideration.
Key Clinical Pitfalls
- Relying on preserved FVC/FEV1: Spirometry appears deceptively normal due to opposing mechanical effects of emphysema and fibrosis 1
- Missing pulmonary hypertension: Extremely common and dramatically worsens prognosis
- Undertreatment: Most patients don't receive antifibrotics despite meeting criteria 2
- Delayed transplant referral: Given poor prognosis, evaluate early rather than waiting for severe decline